| Date | Title | Description |
| 28.10.2024 | WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development | SHANGHAI, Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of WuXia™ RidGS, a high-yield gluta... |
| 16.10.2024 | WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year | HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The... |
| 23.09.2024 | WuXi Biologics Included in Hang Seng ESG 50 Index | HONG KONG, Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has been included in the Hang Seng ES... |
| 11.09.2024 | The Rising Tide of Genomic Innovation: MGI's CycloneSEQ Technology and the Political Storm Surrounding Biotech | In the world of biotechnology, innovation is the lifeblood that fuels progress. MGI Tech Co., Ltd. has recently unveiled its latest advancements in nanopore sequencing technology, the CycloneSEQ-WT02 and CycloneSEQ-WY01. These products prom... |
| 07.09.2024 | Democrat to vote against bill restricting China's WuXi Biologics, BGI | Boards, Policy & RegulationHuman Rights
Democrat to vote against bill restricting China's WuXi Biologics, BGI
By Karen FreifeldSeptember 7, 20243:30 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Emai... |
| 21.08.2024 | WuXi XDC: A Surge in Growth and Ambition in the Bioconjugate Market | WuXi XDC Cayman Inc. is riding a wave of success. The company, a titan in the Contract Research, Development, and Manufacturing Organization (CRDMO) sector, has unveiled impressive financial results for the first half of 2024. With a revenu... |
| 21.08.2024 | WuXi Biologics Reports Solid 2024 Interim Results | Revenue increased by 1.0% YoY to RMB 8,574.2 million
Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%
Added 61 new integrated projects, including 4 from late-phase and commerci... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit increased by 175.5% to RMB 488 million,... |
| 20.08.2024 | WuXi XDC Reports Strong Business Updates with Superior Financial Results in 1H 2024: Poised for Future Growth | Revenue surged by 67.6% YoY to RMB 1,665 million
Gross profit surged by 133.4% to RMB 535 million, with a gross profit margin of 32.1%, a 9.0 percentage points increase compared to 1H 2023.
Net profit increased by 175.5% to RMB 488 million,... |
| 08.08.2024 | WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers | Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispecific antibody platform WuXiBody™
Collabor... |
| 01.08.2024 | WuXi Biologics' Four Manufacturing Facilities and Biosafety Testing Center Certified Again by European Medicines Agency for Ten Biologics | WUXI and SUZHOU, China, Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that four manufacturing facilities... |
| 24.07.2024 | Glanua secures strategic investment from Rabobank | Water infrastructure engineering group Glanua has secured funding from Rabobank as targets annual sales of €400m by 2028.
The level of funding offered by Rabobank has not been disclosed, but Glanua said it would enhance its capacity to scal... |
| 10.07.2024 | WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year | SHANGHAI, July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been named as a constituent company of t... |
| 30.04.2024 | WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment | The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders.
The Company made remarkable progress in tackling climate change, achieving a 29% intensit... |
| 26.03.2024 | WuXi Biologics Reports Solid 2023 Annual Results | Revenue Increased by 11.6% Y-o-Y to RMB17,034.3 Million
Gross Profit Rose by 1.5% to RMB6,827.9 Million
Non-COVID Revenue Achieved 37.7% Y-o-Y Growth, Strong Momentum Sustained
Non-COVID Late-Phase and Commercial Manufacturing Revenue Grew ... |
| 25.03.2024 | WuXi XDC Delivers Outstanding Performance in 2023 with over 110% Year-On-Year Growth for Both Revenue and Adjusted Net Profit and Achieves Significant Corporate Milestones | Revenue reached RMB 2,124 million, an increase of 114% compared with Year 2022
Adjusted net profit reached RMB 412 million, an increase of 112% compared with Year 2022
Total number of integrated projects increased to 143
50 new integrated p... |
| 05.03.2024 | WuXi Biologics Achieves Leadership Level in 2023 CDP Climate Change Assessment | SHANGHAI, March 5, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been recognized for outstanding performance in... |
| 21.02.2024 | WuXi Biologics Recognized as Both Industry and Regional ESG Top-Rated Company by Morningstar Sustainalytics | Named Top-Rated for fourth consecutive year
Committed to generating long-term value for all stakeholders
SHANGHAI, Feb. 21, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Developmen... |
| 31.01.2024 | WuXi XDC Enters into Partnership with Multitude Therapeutics and HySlink Therapeutics, Novel Linker-Payload Technology Enabling Clients to Accelerate ADC Discovery and Development | SHANGHAI, Jan. 31, 2024 /PRNewswire/ -- WuXi XDC (2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market; and Multitude Therapeutics, a clin... |
| 31.01.2024 | WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland | - First manufacturing run successful for MFG7 facility at the Ireland site
- Largest manufacturing scale to date achieved by combining four 4,000-liter single-use bioreactors
DUNDALK, Ireland, Jan. 31, 2024 /PRNewswire/ -- WuXi Biologics (&... |
| 25.01.2024 | WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect | - WuXiaADCC PLUSTM is designed to meet the market need for improved antibody therapeutic efficacy by producing afucosylated antibodies with the ability to increase antibody-dependent cell-mediated cytotoxicity (ADCC), providing diverse biop... |
| 24.01.2024 | WuXi XDC and Celltrion Sign MOU for Integrated Services for Antibody-Drug Conjugates (ADCs) | SHANGHAI and INCHEON, South Korea, Jan. 24, 2024 /PRNewswire/ -- WuXi XDC(2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on ADC and the other types of bioconjugate market, and Celltr... |
| 17.01.2024 | WuXi Biologics Granted U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™ | SHANGHAI, Jan. 17, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that a patent for WuXiBodyTM – a proprietary, h... |
| 08.01.2024 | WuXi Biologics to Increase Manufacturing Capacity in Massachusetts | The added capacity will further enhance WuXi Biologics' commercial manufacturing capabilities in the U.S.
The site is expected to employ 250 people when fully operational.
WORCESTER, Mass., Jan. 8, 2024 /PRNewswire/ -- WuXi Biologics ("... |
| 13.12.2023 | WuXi Vaccines Wins Second Consecutive "Best Vaccine CMO Award" at AVEA 2023 | SINGAPORE, Dec. 13, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine Contract Development and Manufacturing Organization (CDMO), was named "Best Vaccine CMO of the Year" for the second consecutive year at the 2023 Asia... |
| 08.12.2023 | WuXi Biologics Awarded Highest Platinum Medal by EcoVadis Sustainability Rating | Ranked in top 1% of the over 100,000 companies evaluated
Recognized for outstanding performance across all areas: Environment, Labor & Human Rights, Ethics, and Sustainable Procurement
Seen as a trusted partner by global clients for its... |
| 06.12.2023 | WuXi Vaccines Passes First GMP Audit by a Global Vaccine Leader | SUZHOU, China, Dec. 6, 2023 /PRNewswire/ -- WuXi Vaccines, a leading global vaccine CDMO (Contract Development and Manufacturing Organization), today announced it has successfully passed an on-site GMP audit by a global vaccine leader at it... |
| 22.11.2023 | WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale | By leveraging WuXiUPTM, WuXi Biologics has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale
This end-to-end continuous bioprocess, which is in place fo... |
| 17.11.2023 | WuXi XDC Successfully Listed on the Main Board of Hong Kong Stock Exchange | HONG KONG, Nov. 17, 2023 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC" or the "Company", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization ("CRDMO") focused... |
| 08.11.2023 | WuXi Biologics Receives AAA MSCI ESG Rating | SHANGHAI, Nov. 8, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has received an AAA rating from Morgan Stanley Capi... |
| 20.10.2023 | WuXi XDC Named Best CDMO Winner at 2023 World ADC Awards | SHANGHAI, Oct. 20, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract, Research, Development, and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, announced it has been named the winner of the &... |
| 18.10.2023 | WuXi XDC and HKSTP Join Forces to Promote Development of Bioconjugate Drug Industry in Hong Kong | Hong Kong Science and Technology Parks Corporation (HKSTPC) and WuXi XDC signed a cooperation framework agreement to jointly promote the establishment of a contract research, development and manufacturing organization(CRDMO) value chain in ... |
| 17.10.2023 | WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality | WuXiUI™ ultra-intensified fed-batch platform offers a new process option for maximum flexibility to meet various clients' needs in biologics development and manufacture. The platform can significantly improve productivity and quality, and r... |
| 02.10.2023 | WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease | WUXI, China, Oct. 2, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner, Amicus Therapeutics (&qu... |
| 26.09.2023 | WuXi Vaccines Launches Its First Vaccines CDMO Site in China | SUZHOU, China, Sept. 26, 2023 /PRNewswire/ -- WuXi Vaccines, a leading contract development and manufacturing organization (CDMO) focused on vaccine discovery, development, and manufacturing, has launched its first standalone vaccines CDMO ... |
| 20.09.2023 | WuXi XDC Launches New Commercial Manufacturing Facilities | New commercial facilities offer one-stop manufacturing services for antibody intermediates, bioconjugate drug substance and drug product
Doubled capacity provides greater support to the rapidly growing global bioconjugate industry
WUXI, Chi... |
| 11.08.2023 | WuXi XDC and Boostimmune Sign MOU for Integrated Services | SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- WuXi XDC, a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the ADC and broader bioconjugate market, and Boostimmune, a biotech company dedicated to dev... |
| 11.08.2023 | WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services | SHANGHAI, Aug. 11, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Boostimmune, a biotech company dedicated to developing next... |
| 27.06.2023 | Pharmadule Morimatsu and WuXi Biologics Reached Global Strategic Partnership | SHANGHAI, June 27, 2023 /PRNewswire/ -- June 26th, 2023, Pharmadule Morimatsu and WuXi Biologics officially entered into a global strategic cooperation for the Singapore CRDMO Center project of WuXi Biologics.
As leaders in their respective... |
| 01.06.2023 | WuXi Biologics to Increase Manufacturing Capacity in Germany | - In response to global clients' increasing demand for contract manufacturing services, WuXi Biologics is expanding its capacity for drug substance and drug product in Germany
- The investment promotes the creation of additional high-skille... |
| 22.05.2023 | WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations | DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that the International Society for Pha... |
| 16.05.2023 | WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients | WuXi Biologics is the manufacturing partner of InflaRx for Gohibic (vilobelimab), a first-in-class monoclonal anti-C5a antibody.
InflaRx received emergency use authorization (EUA) from the FDA for Gohibic (vilobelimab) for the treatment of ... |
| 28.04.2023 | WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability | The Report outlines new goals of net-zero GHG emissions across all operations by 2050 and a 10% reduction of waste intensity by 2027 compared with 2022.
The Company makes remarkable progress on environmental goals, achieving its water consu... |
| 28.03.2023 | WuXi Biologics Congratulates Amicus Therapeutics on European Commission Approval for Pombiliti™ in Patients with Late-Onset Pompe Disease | WUXI, China, March 28, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates its strategic partner Amicus Therapeutics (&q... |
| 22.03.2023 | WuXi Biologics Reports Remarkable 2022 Annual Results | Revenue Increased by 48.4% Y-o-Y to RMB15,268.7 Million
Gross Profit Increased by 39.2% Y-o-Y to RMB6,724.0 Million
Adjusted Net Profit Rose by 47.1% to RMB5,053.9 Million
Non-COVID Revenue Achieved 63% Y-o-Y Growth, Strong Momentum Continu... |
| 05.01.2023 | WuXi Biologics and GSK Enter into License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers | WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technolo... |
| 26.12.2022 | GeneQuantum and WuXi XDC have entered into strategic cooperation to empower innovative bioconjugates development | SUZHOU, China, Dec. 26, 2022 /PRNewswire/ -- GeneQuantum Healthcare (GQ), a global innovative biotechnology company dedicated to the development of the next generation bioconjugate drugs , and WuXi XDC, a leading global Contract Research, D... |
| 16.12.2022 | WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List | SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd... |
| 16.12.2022 | WuXi Biologics (Shanghai) Co., Ltd. Removed from the U.S. Commerce Department's Unverified List | SHANGHAI, Dec. 16, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics (Shanghai) Co., Ltd... |
| 27.10.2022 | WuXi Biologics Provides Corporate Updates | SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress.
Recent Business M... |
| 26.10.2022 | WuXi Biologics Announces GMP Release of 48,000L Commercial Drug Substance Manufacturing Facility in Hebei, China | - The 11th drug substance facility is released for cGMP operation in the WuXi Biologics' global manufacturing network. This new facility enhances the company's capability of providing commercial manufacturing at 4,000L to 20,000L scale, fac... |
| 24.10.2022 | WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities | WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP
HANGZHOU, China, Oct. 24, 2022 /PRNewswir... |
| 24.10.2022 | WuXi Biologics Released a New cGMP Drug Product Manufacturing Facility to Support End-to-End Services for Diversified Modalities | WuXi Biologics adds further capacity and capability for drug product fill & finish, providing global customers with end-to-end integrated solutions for diversified modalities, including mRNA-LNP
HANGZHOU, China, Oct. 23, 2022 /PRNewswir... |
| 14.10.2022 | WuXi Biologics Receives "Best CDMO Award of the Year" | SHANGHAI, Oct. 13, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the... |
| 14.10.2022 | Will the Taiwan Semiconductor Manufacturing Company of Drugs Be in East Asia? | On Aug. 25, President Biden signed the monumental $52.7 billion CHIPS and Science Act into law. The legislation is aimed to address the semiconductor manufacturing bottleneck in East Asia, namely the near-monopoly held on the industry by th... |
| 14.10.2022 | WuXi Biologics Receives "Best CDMO Award of the Year" | SHANGHAI, Oct. 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received the "Best CDMO Award of the... |
| 12.10.2022 | WuXi Biologics and Toregem BioPharma Sign MOU for Development of Anti-USAG-1 Antibody | SHANGHAI, Oct. 11, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), and Toregem BioPharma, a biotech startup company from Kyoto Uni... |
| 10.10.2022 | Indian manufacturer under scrutiny after cough syrups linked to deaths in West Africa | LONDON — Back when Jack O’Meara and Quin Wills were initially setting up Ochre Bio, they jumped from their home base in the UK to the US primarily so they could establish a syndicate of investors who could fund their startup as they began t... |
| 10.10.2022 | J&J's Janssen unveils PhII ulcerative colitis data for Tremfya combo, looking to expand the drug's footprint | As J&J’s Janssen has worked to expand the use of Tremfya over the past few years, its latest data show that it is poised to engage in treatment for ulcerative colitis.
On Monday, the company displayed data from a Phase I... |
| 10.10.2022 | The crown jewel in Merck’s $11.5B Acceleron buyout just cleared a pivotal PhIII | Merck consistently spotlighted the multibillion-dollar sales potential of sotatercept, the lead drug in Acceleron’s pipeline, as it explained to investors why it wagered $11.5 billion to acquire the biotech late last year... |
| 10.10.2022 | After $10B in market value lost, China's WuXi Biologics removed from US unverified list | WuXi Biologics has cause to celebrate as it finds itself removed from the US Department of Commerce’s unverified list.
The China-based contract research and manufacturing giant was initially placed on the list in Feb... |
| 10.10.2022 | WuXi Biologics Co., Ltd. Removed from Unverified List | WUXI, China, Oct. 10, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio", 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its subsidiary WuXi Biologics Co., Ltd. locate... |
| 29.09.2022 | WuXi Biologics Topped Off the Steel on its Commercial Biomanufacturing Facility in Worcester, Massachusetts | WORCESTER, Mass., Sept. 29, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO), held a topping-off ceremony, in partnership with the Worcester... |
| 20.09.2022 | WuXi Biologics' Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA | WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities ... |
| 31.08.2022 | WuXi Biologics Announces GMP Release of Its First North American Biomanufacturing Facility in Cranbury, New Jersey | CRANBURY, N.J., Aug. 31, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), today announced the release of its GMP phase I drug subst... |
| 17.08.2022 | WuXi Biologics Reports Strong 2022 Interim Results | Revenue Increased by 63.5% Y-o-Y to RMB7,206.4 Million
Gross Profit Increased by 48.6% Y-o-Y to RMB3,413.2 Million
Net Profit Grew by 39.2% Y-o-Y to RMB2,621.2 Million
Adjusted Net Profit Rose by 60.9% to RMB2,914.9 Million
Total Backlog Re... |
| 17.08.2022 | WuXi Biologics Again Selected as Constituent of FTSE4Good Index Series | SHANGHAI, Aug. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global leading Contract Research, Development and Manufacturing Organization (CRDMO), announced today that it has once again been selected as a const... |
| 20.07.2022 | Chinese biotech firm allots $1.4b for Singapore expansion | InvestmentsNews
Thao Lam La · 2d ago · 2 min readChinese biotech firm allots $1.4b for Singapore expansion
WuXi Biologics, a China-based biopharmaceutical firm, announced it will invest S$2 billion (US$1.4 billion) over the next 10 years to... |
| 19.07.2022 | WuXi Biologics serves up $1.4B expansion of research and manufacturing center in Singapore | While WuXi Biologics is continuing to work with US regulators on inspections of its facilities, the company is also looking to expand one of its manufacturing sites in Asia.
On Tuesday, the company announced that ... |
| 19.07.2022 | WuXi Biologics Plans to Build a Comprehensive CRDMO Center in Singapore | This investment will establish a cutting-edge, fully integrated CRDMO center in Singapore, including a research and development service center and large-scale drug substance and drug product manufacturing facilities for biologics
The invest... |
| 12.07.2022 | WuXi Vaccines Received First GMP Certificate of QC Potency Lab from Ireland Health Products Regulatory Authority | - The first GMP certificate that WuXi Vaccines has received from the regulatory agency
- A critical step for WuXi Vaccines to enable the manufacturing of commercial vaccine products in its Dundalk facility and supplying the global market fo... |
| 08.07.2022 | WuXi XDC and AbTis Sign Memorandum of Understanding for Development and Manufacturing of Antibody Drug Conjugates | SHANGHAI and SEOUL, South Korea, July 8, 2022 /PRNewswire/ -- WuXi XDC, a global leading CRDMO (Contract Research, Development and Manufacturing Organization) dedicated to end-to-end bioconjugates services, and AbTis, a Korean biotechnology... |
| 05.07.2022 | WuXi Biologics Extends Capabilities to Include Development and cGMP Manufacturing for Microbial-Derived Products | WuXi Biologics expands its extensive integrated CRDMO services by offering development and cGMP manufacturing for microbial-derived products.
HANGZHOU, China, July 5, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a g... |
| 06.06.2022 | WuXi Biologics Launches First Commercial Drug Product Facility for Pre-Filled Syringes | WuXi Biologics offers global partners high-efficiency and high-quality manufacturing services for clinical trial and commercial supply by increasing pre-filled syringes (PFS) capacity to 17 million units per year.
WuXi Biologics has establi... |
| 28.04.2022 | WuXi Biologics' 2021 ESG Report Reveals Company's Strong Commitment to Overall Sustainability | - WuXi Biologics has aligned its ESG strategy with the United Nations Sustainable Development Goals (SDGs), as well as with its stakeholders' interests in sustainable business performance.
- One example of WuXi Biologics' contribution to so... |
| 15.04.2022 | WuXi Biologics Receives Bioprocessing Excellence Award from IMAPAC | SINGAPORE, April 15, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global Contract Research, Development and Manufacturing Organization (CRDMO) service company, today announced that the company received the award f... |
| 23.03.2022 | WuXi Biologics Achieved Record Growth and Profitability in 2021 | Banner Year for Commercial Manufacturing
Revenue Increased by 83.3% Y-o-Y to RMB10,290.1 Million
Gross Profit Increased by 90.6% Y-o-Y to RMB4,828.9 Million
Net Profit Grew by 107.3% Y-o-Y to RMB3,508.6 Million
Adjusted Net Profit Rose by 1... |
| 14.03.2022 | WuXi Biologics Recognized as 2022 Top-Rated ESG Company by Sustainalytics | SHANGHAI, March 14, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, has been recognized as the Industry Top-Rated Company in 2022 by Sustainalytics, a global provider of Environmental, S... |
| 02.03.2022 | WuXi Biologics Wins CMO Leadership Awards in All Six Core Categories for Fifth Consecutive Year | SHANGHAI, March 2, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global CRDMO service company, today announced that the company has won the 2022 CMO Leadership Awards in all six core categories (i.e., capabilities,... |
| 08.02.2022 | WuXi Biologics Statement | SHANGHAI, Feb. 8, 2022 /PRNewswire/ -- We have been made aware of a recent U.S. Commerce Department announcement that two WuXi Biologics (Cayman) subsidiaries in Shanghai and Wuxi will be added to the department's "Unverified List"... |
| 18.01.2022 | WuXi Biologics Cayman : Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility | WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full c... |
| 18.01.2022 | WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility | WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements.
WUXI, China, Jan. 18, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi B... |
| 07.01.2022 | WuXi Biologics Cayman : Vaccines and BravoBio Sign Letter of Intent for Long-Term Collaboration – Accelerating Development and Commercial Manufacturing of Innovative Vaccines | WuXi Vaccines and BravoBio Sign Letter of Intent for Long-Term Collaboration - Accelerating Development and Commercial Manufacturing of Innovative Vaccines
Shanghai, China, January 7, 2022 - WuXi Vaccines, a world-leading vaccine Contract D... |
| 28.12.2021 | WuXi Biologics Cayman : and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody | WuXi Biologics and ImmuneOncia Sign MOU for Development and Manufacturing of Anti-PD-L1/CD47 Bispecific Antibody
SHANGHAI, China, and SEOUL, South Korea, December 28, 2021 - WuXi Biologics ("WuXi Bio") (2269.HK), a global company ... |
| 22.12.2021 | WuXi Biologics Cayman : Wins 2021 Hong Kong Corporate Governance Award | WuXi Biologics Wins 2021 Hong Kong Corporate Governance Award
Hong Kong, December 21, 2021 - WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that the... |
| 23.11.2021 | WuXi Biologics Cayman : First GMP Production at 24,000L Line of MFG5 Facility Successfully Completed at WuXi Biologics | First GMP Production at 24,000L Line of MFG5 Facility Successfully Completed at WuXi Biologics
MFG5 60,000L capacity is all put in use. Total capacity increased to 150,000L to support late-phase and commercial manufacturing projects.
Wuxi, ... |
| 01.11.2021 | WuXi Biologics Launches a New GMP Commercial Drug Product Facility | Enhances drug product services for projects at various stages, with an emphasis on late and commercial stage production
Increases up to 60 million vials for commercial drug production per year
Consolidates WuXi Biologics' pioneering the app... |
| 28.10.2021 | WuXi Biologics Completes GMP Inspection by Health Canada for Drug Substance Facility | - Successfully completed nearly 20 regulatory inspections in total, including 13 regulatory inspections since the start of 2021
WUXI, China, Oct. 28, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company wit... |
| 01.09.2021 | WuXi Biologics Received First Manufacturing License from Japan and Completed 12 Global Regulatory Inspections in 2021 Year to Date | Successfully completed 12 regulatory inspections so far this year
WUXI, China, Sept. 1, 2021 /PRNewswire/ -- WuXi Biologics (WuXi Bio) (2269.HK), a global company with leading open-access biologics technology platforms, today announced that... |
| 23.08.2021 | WuXi Biologics Reports Strong 2021 Interim Results | Revenue Increases by 126.7% Y-o-Y to RMB4,406.8 Million
Gross Profit Grows by 191.7% Y-o-Y to RMB2,296.8 Million
Adjusted Net Profit Attributable to Owners of the Company Increases by 163.0% Y-o-Y to RMB1,768.7 Million
Gross and Net Profit ... |
| 02.08.2021 | WuXi Biologics Biosafety Testing Facility Received Second EMA GMP Certificate | SUZHOU, China, Aug. 2, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that only 13 months after receiving its first GMP certificate, ... |
| 26.07.2021 | WuXi Biologics : Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility | First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system
Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed"
LEVERKUS... |
| 26.07.2021 | WuXi Biologics Received Commercial Manufacturing License from German Health Authorities for its German Drug Product Facility | First GMP manufacturing authorization outside of China, validating WuXi Biologics' world-class quality system
Only 12 months from facility qualification to licensure demonstrating global adoption of "WuXi Biologics Speed"
LEVERKUS... |
| 15.07.2021 | WuXi Biologics Cayman : Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures | NEW JERSEY and HANGZHOU, CHINA, Jul 15, 2021 - (ACN Newswire) - - Adlai Nortye Ltd. (hereinafter referred to as "Adlai Nortye"), a global biopharmaceutical company focused on developing innovative oncology drugs, today announced t... |
| 10.06.2021 | WuXi XDC and LegoChem Biosciences Signed Memorandum of Understanding for the Development and Manufacturing of Antibody-drug Conjugates | WUXI, China and DAEJEON, South Korea, June 10, 2021 /PRNewswire/ -- WuXi XDC ("XDC"), a global CDMO company dedicated to end-to-end bioconjugates services, and LegoChem Biosciences (141080KS, "LCB"), today announced that... |
| 27.05.2021 | WuXi Biologics and OncoC4 Establish Exclusive CDMO Partnership | SHANGHAI and ROCKVILLE, Md., May 27, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and OncoC4, Inc., a privately-held, clinical-stage biopharm... |
| 14.05.2021 | WuXi Biologics and WuXi STA Jointly Established WuXi XDC to Provide Fully Integrated Bioconjugate CDMO Services | WUXI, China, May 14, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, and WuXi STA, a subsidiary of WuXi AppTec, today announced that a joint ven... |
| 07.05.2021 | WuXi Biologics Completed Three Acquisitions to Enhance its Global Network | SHANGHAI, May 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that it has completed the acquisitions of a Bayer manufacturing facil... |
| 18.03.2021 | Pfizer lays down its hand on Chinese biosims, offloading its 3-year-old plant to WuXi Biologics as competition grows | Pfizer is in downsizing mode after a hefty spinoff of its Upjohn generics unit and a full-scale pivot toward branded meds. That move left Pfizer’s biosim unit in limbo, and now the drugmaker is making an early exit from the... |
| 18.03.2021 | Merck KGaA adds 350 workers at French site to build capacity for 'single-use' tech for Covid-19 vaccines, therapies | Germany’s Merck KGaA has seen a growth spurt in recent months driven by sky-high demand for Covid-19 drugs and vaccines. Now, the company is fleshing out a French production site to produce one-and-done production tech that ca... |
